FDA panel recommends Edwards’ heart valves for high-risk patients
Late Wednesday, a U.S. Food and Drug Administration panel recommended that Edwards Lifesciences (NYSE:EV) transcatheter aortic valve replacement procedure be approved for patients with high risk to the alternative open-heart surgery. Late last year, Edwards became the first company in the U.S. to win FDA approval for using the so-called TAVR procedure on patients with […]